Full history for every metric is available with a Kvantra account
Pear Therapeutics, Inc. (PEAR)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 33 | 9 | 4 | 13 | 13 |
| Operating profit | $m | -123 | -123 | |||||
| Net profit | $m | - | - | 12 | -101 | -20 | -24 | 25 |
| EPS reported | $ | -0.17 | 0.17 | |||||
| Operating cashflow per share | $ | -0.82 | -0.82 | |||||
| Capex per share | $ | 0.03 | 0.03 | |||||
| FCF per share | $ | -0.85 | -0.85 | |||||
| Free cash flow | $m | -117 | -117 | |||||
| Net debt | $m | -22 | -32 | |||||
| Book value equity | $m | 31 | 31 | |||||
| Book value per share | $ | 0.22 | 0.22 | |||||
| Number of shares | m | 138.71 | 138.71 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 5.35 | 0.13 | |||||
| P/S LTM | x | 12.89 | 0.32 | |||||
| P/FCF LTM | x | -1.39 | -0.03 | |||||
| EV/EBITDA LTM | x | -2.32 | 0.48 | |||||
| EV/Sales LTM | x | 12.05 | -2.18 | |||||
| Earnings Yield LTM | % | -14.50% | -586.14% | |||||
| FCF Yield | % | -71.71% | -2870.4% | |||||
| Quality | ||||||||
| ROE | % | -77.62% | -39.23% | |||||
| ROIC | % | -51.64% | -51.64% | |||||
| Operating margin | % | -971.72% | -971.72% | |||||
| Gross margin | % | 35.54% | 35.54% | |||||
| FCF/Sales | % | -924.57% | -924.57% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +201.66% | +201.66% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.12 | -3.12 | |||||
| Net Debt/EBITDA | x | 0.16 | 0.16 | |||||
| EBIT/Net interest | x | -31.69 | -31.69 | |||||
| Net debt/market cap | % | -13.24% | -778.34% | |||||
| Net debt/Equity | x | -0.71 | -1.04 | |||||
| Gross debt/equity | x | 1.23 | 1.23 | |||||
Company overview
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and non-central nervous system conditions like gastrointestinal, oncological, and cardiovascular disorders. Founded in 2013, Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Pear Therapeutics, Inc. (PEAR)
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and non-central nervous system conditions like gastrointestinal, oncological, and cardiovascular disorders. Founded in 2013, Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free